Editorial: How Will Aducanumab Approval Impact AD Research?

Overview

Journal J Prev Alzheimers Dis

Specialty Neurology

Date 2021 Sep 29

PMID 34585209

Citations 3

Authors

M W Weiner

P S Aisen

L A Beckett

R C Green

W Jagust

J C Morris

O Okonkwo

R J Perrin

R C Petersen

M Rivera Mindt

A J Saykin

L M Shaw

A W Toga

J Q Trojanowski

Affiliations

Soon will be listed here.

Citing Articles

Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies.

Izmailova E, Maguire R, McCarthy T, Muller M, Murphy P, Stephenson D Clin Transl Sci. 2022; 16(3):383-397.

PMID: 36382716 PMC: 10014695. DOI: 10.1111/cts.13461.

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?.

Wallin A, Alladi S, Black S, Chen C, Greenberg S, Gustafson D Cereb Circ Cogn Behav. 2022; 3:100044.

PMID: 36324416 PMC: 9616233. DOI: 10.1016/j.cccb.2022.100044.

Alzheimer's disease drug development pipeline: 2022.

Cummings J, Lee G, Nahed P, Kambar M, Zhong K, Fonseca J Alzheimers Dement (N Y). 2022; 8(1):e12295.

PMID: 35516416 PMC: 9066743. DOI: 10.1002/trc2.12295.

References

Cummings J, Aisen P, Apostolova L, Atri A, Salloway S, Weiner M . Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021; 8(4):398-410. PMC: 8835345. DOI: 10.14283/jpad.2021.41. View